Peter Schiemann

Peter Schiemann is a seasoned professional in the biopharmaceutical industry, currently serving as Managing Partner at Widler & Schiemann Ltd since March 2012, where the focus is on customer-centric clinical development. As CEO and Chairman of the Board at Ymmunobio since September 2021, Peter leads efforts to innovate new tumor markers shown to be present in multiple solid tumors. In addition, Peter co-founded iQure Pharma Inc. in January 2019, focusing on therapeutics for neuropathic pain, and holds the position of Associate Partner at LSCP Life Sciences Consulting Partners. An investor in private ventures since March 2012, Peter previously held significant roles at Hoffmann-La Roche, including Global Head of Quality Risk Management, and served as a consultant for PricewaterhouseCoopers. Educational qualifications include a PhD in Human Biology and various postgraduate certificates in Pharmaceutical Medicine, Marketing Strategy, and Global Enterprise Management.